Enrolling Trials at Retina Research Center

Retina Research Center is currently participating in 20 Phase I-III clinical trials, 12 of which are currently enrolling.

**Wet Age-Related Macular Degeneration**

**Genentech Archway**: A Phase III study evaluating the efficacy and safety of the Port Delivery System (PDS) with ranibizumab in patients with neovascular AMD

**Genentech Portal**: An open-label extension study evaluating long-term safety and tolerability of the port delivery system (For patients that completed Phase II or Phase III parent study)

**Novartis Merlin**: A Phase III study to assess safety and efficacy of brolucizumab 6mg q4 weeks compared to aflibercept 2mg q4 weeks in patients with neovascular AMD

**Santen 36-002 Avante**: A Phase II Study assessing the efficacy and safety of intravitreal injections of DE-122 in combination with Lucentis compared to Lucentis monotherapy in subjects with neovascular AMD

**Kodiak KSI-CL-101**: A Phase 1b Open-Label study assessing the bioactivity, tolerability and safety of multiple intravitreal injections of KSI-301 in patients with wet AMD, DME and RVO

**Non-proliferative Diabetic Retinopathy**

**Boehringer-Ingelheim Protocol 1386.12 ROBIN**: A Phase IIa study evaluating safety and efficacy of oral BI 1467335 in patients with moderate to severe diabetic retinopathy

**Diabetic Macular Edema**

**Genentech Yosemite**: A Phase III study to evaluate efficacy and safety of RO6867461 in patients with diabetic macular edema

**Novartis Kestrel**: A Phase III evaluating the efficacy of brolucizumab compared to Eylea in patients with diabetic macular edema.

**Kalvista KVD001-201**: A Phase 2 study to assess safety and efficacy of intravitreal plasma kallikrein inhibitor, KVD001, in patients with center-involved DME who have had prior anti-VEGF treatment

**DRCR AC**: A randomized trial comparing intravitreal Eylea versus intravitreal Avastin and deferred Eylea for treatment of center-involved DME

**Dry AMD - Geographic Atrophy**

**Gemini Clarity**: A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with non-central GA who are carriers of high-risk genetic complement variants associated with dry AMD

**Macular Telangiectasia**

**Mactel NHOR**: A natural history observation and registry study of Macular Telangiectasia Type II

**Neurotech NTMT-03-B Renexus**: A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

**CONTACT US**

Brian B Berger, MD—bberger@e-retina.net  
Saradha Chexal, MD—schexal@e-retina.net  
Ivana Gunderson—igunderson@e-retina.net  
Ryan Parmoon—rparmoon@e-retina.net  
Chirag Jhaveri, MD—cjhaveri@e-retina.net  
Gowtham Jonna, MD—gjonna@e-retina.net  
Daniela Wilson—dwilson@e-retina.net  
Valerie Gatavaski—vgatavaski@e-retina.net  
512-279-1251  
www.retinaresearchcenter.com